Exchange: NYSE·Updated 11:04 AM EDT
News
all
press releases
Is DaVita (DVA) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
More News
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.
Zacks
DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
DaVita's Q2 earnings call highlights mortality-led volume gains and broader middle molecule access, while management held 2026 guidance amid reimbursement pressure.
Zacks
DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates
DaVita HealthCare (DVA) delivered earnings and revenue surprises of +0.25% and +0.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
DaVita Inc. Reveals Rise In Q2 Bottom Line
(RTTNews) - DaVita Inc. (DVA) reported a profit for its second quarter that Increases, from last year...
Nasdaq News: Markets
DaVita Inc. 2nd Quarter 2026 Results
DaVita Inc. 2nd Quarter 2026 Results DaVita Inc. 2nd Quarter 2026 Results PR Newswire DENVER, Aug. 4, 2026 DENVER, Aug. 4, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June30, 2026."Thanks to the outstanding efforts of our teammates...
PR Newswire
Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?
DVA's Q2 results are likely to benefit from volume growth and RPT recovery, but payor mix pressure and spending on technology could limit margin gains.
Zacks
Quest Diagnostics Raises 2026 Outlook as Testing Demand Accelerates
DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project costs could temper the payoff.
Zacks
Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?
Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.
Zacks
Quest Diagnostics Growth Drivers Investors Should Watch Now in 2026
DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.
Zacks

Advertisement|Remove ads.